论文部分内容阅读
钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是一种能够特异性抑制肾小球近端小管,对滤过葡萄糖重吸收,使过量的葡萄糖从尿液中排出,直接降低血糖的药物。目前临床研究表明,SGLT2抑制剂具有良好的药效、安全性和耐受性,能够有效地降低血糖,增加尿液中葡萄糖的排出量,可能成为一种新的治疗2型糖尿病(T2DM)高血糖的方法。现就SGLT2抑制剂在T2DM治疗方面的最新研究进展予以综述。
The sodium-glucose cotransporter 2 (SGLT2) inhibitor is a drug that specifically inhibits glomerular proximal tubules, re-absorbs filtered glucose, excretes excess glucose from the urine, and directly reduces blood sugar. The current clinical studies have shown that SGLT2 inhibitors have good efficacy, safety and tolerability, can effectively lower blood glucose and increase glucose in urine output, may be a new type of treatment of type 2 diabetes (T2DM) high Blood sugar method. Now on the SGLT2 inhibitors in the treatment of T2DM research are reviewed.